SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

28 Oct 2023 Evaluate
A decrease in the sales to Rs. 5752.10 millions was observed for the quarter ended September 2023. The sales stood at Rs. 6374.70 millions during the similar quarter previous year.Profit after Tax for the quarter ended September 2023 saw a decline of -52.11% from Rs. 3110.70 millions to Rs. 1489.60  millions.The company reported a degrowth in operating Profit to 2186.80 millions from 2559.30 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 5752.10 6374.70 -9.77 11065.70 12303.70 -10.06 24247.60 26109.90 -7.13
Other Income 360.70 242.40 48.80 695.30 422.60 64.53 1010.50 626.50 61.29
PBIDT 2186.80 2559.30 -14.55 3628.50 4658.00 -22.10 9099.10 8983.80 1.28
Interest 27.30 33.80 -19.23 56.00 70.20 -20.23 133.90 104.90 27.65
PBDT 2159.50 4414.70 -51.08 3572.50 5113.70 -30.14 9295.20 8878.90 4.69
Depreciation 154.30 262.50 -41.22 309.80 527.60 -41.28 1055.10 1150.00 -8.25
PBT 2005.20 4152.20 -51.71 3262.70 4586.10 -28.86 8240.10 7728.90 6.61
TAX 515.60 1041.50 -50.49 837.80 1149.90 -27.14 2000.80 1603.30 24.79
Deferred Tax 42.20 -31.90 -232.29 30.10 -186.00 -116.18 -519.10 -359.30 44.48
PAT 1489.60 3110.70 -52.11 2424.90 3436.20 -29.43 6239.30 6125.60 1.86
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 38.02 40.15 -5.31 32.79 37.86 -13.39 37.53 34.41 9.06

Pfizer Share Price

4815.00 3.95 (0.08%)
11-May-2026 09:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.00
Dr. Reddys Lab 1281.55
Cipla 1339.50
Zydus Lifesciences 932.80
Lupin 2282.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×